Viewpoint

If you think it’s hard to do a biotech start up, try doing it in Poland. You’ll face international condescension, local incredulity and the mysteries of Polish law, says Charles Goldfinger.

On 26 January, in London, Science|Business organised a roundtable of executives in the biotech industry to discuss the state of the market. The consensus: investor appetite for biotech companies is on the rise.

There is much more work to do to convince public opinion that bioscience is a force for good, says UK BioIndustry Association chairman Simon Best.

Marc Van Montagu, Europe's founding father of genetically modified crops and a powerful advocate for their acceptance in Europe, speaks to Science|Business News Editor Thomas Lau.

The UK's stem cell community has reacted with collective dismay at the final confirmation that Hwang Woo-suk's claims to have generated patient-specific embryonic stem cell lines were fraudulent. Nuala Moran takes a look.

Forget stem cells, pharmacogenomics and the next big cure - Michael Kenward gazes into his prophecy book to see what the physical sciences have in store for us this year. Or maybe not.

Two New Year's resolutions for the governments around the world that have managed to gum up the economic machinery behind technological development.

Scientists are moving around as never before. And, argues Jean Guinet from the OECD, that’s not necessarily a bad thing.

A politician's gaffe highlights the gender gap in science. Political action, not talk, is what's needed to close it.

Universities are funding more campus companies. Richard L. Hudson on the rules of a very risky game.